RegenPRP has been evaluated for several tendinopathies including:
Evaluate the use of RegenPRP for the treatment of recalcitrant non-insertional Achilles tendinopathies and investigate whether positive outcomes
depend on the age of the patients.3
Retrospective study on 44 patients who had
failed to respond to conservative treatment.
Patients received a total of 3 treatments at weekly intervals. RegenPRP (~ 4 ml) was injected at several sites into the degenerated tendon area. Injections were performed in sterile conditions, without anaesthesia and under ultrasound (US) control (Fig. 1).
Functional evaluation of Achilles tendon was performed using Victorian Institute of Sports Assessment-Achilles questionnaire (VISA-A) at baseline and at 1, 3, 6
and 12 months after the treatment. Patients were divided according to their age in two cohorts (Young <55 years old; Elderly >55 years old) (Fig. 2).
When injected into tendon lesions, RegenPRP showed good outcomes in patients suffering from recalcitrant Achilles non-insertional tendinopathies.
Examine the effect of RegenPRP in chronic
Achilles and patellar tendinopathies.4
Case series study on 21 patients suffering from
chronic tendinopathy for at least 6 months: 14 cases of Achilles tendinopathy and 7 cases of patellar tendinopathy. All patients were sportspeople not responding to conventional treatments.
Patients received a total of 3 infiltrations at weekly intervals. RegenPRP was injected half in the tendon lesion and half in the peritendinous area under US control with local anaesthesia. In addition, patients followed a personalized rehabilitation programme for one month.
Functional evaluation was performed using the VISA questionnaire for Achilles (VISA-A) and patellar tendon (VISA-P) at baseline, at the end of the treatment cycle (3 weeks) and at 12- and 24-months follow-up (figure 3). A numeric rating scale was also used to measure subjective pain.
At the end of the follow-up, patients demonstrated a complete functional recovery and no longer complained of pain. In addition, RegenPRP treatment was well tolerated and without adverse events.
Examine the effect of RegenPRP in twenty-two elbows with tendinitis (epicondylitis n=19 and chronic tricipital tendinitis n=3) after failure with at least two usual treatments.5
Case series study on 22 patients with elbow
tendinopathy not responding to conventional
treatments for 3 to 18 months. Ten patients received
1 injection, 9 patients received 2 injections and 3
patients received 3 injections of RegenPRP.
PRP was injected intra-tendinously by
peppering (point-by-point and nappage
technique), without local anaesthesia.
Evaluation of pain was performed one- and
two-months after the last injection. Follow up
examination was performed after 9 to 22 months.
RegenPRP treatment resulted in long-term improvement of elbow tendinopathies not responding to conventional treatment.